U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07423585) titled 'Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer' on Feb. 13.
Brief Summary: This phase II trial tests the effect of tarlatamab in treating patients with small cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage). SCLC is an aggressive cancer which has a low 5-year survival rate. Tarlatamab is a bispecific antibody that can bind to two different antigens at the same time. Tarlatamab binds to DLL3 which is a protein found on the surface of some types of tumor cells, including small-cell lung cancer, and to CD3 which is present on immune system T-cells (...